Role of tumor-associated macrophages in hematological malignancies

Pathology International

Volumn 65, Issue 4, 2015, Pages 170-176

  Komohara, Yoshihiro ^a   Niino, Daisuke ^b   Ohnishi, Koji ^a   Ohshima, Koichi ^b   Takeya, Motohiro ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD163; CD204; Leukemia lymphoma; Macrophage; TAM; Tumor microenvironment

Indexed keywords

ANGIOGENESIS; B CELL LYMPHOMA; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL INTERACTION; GENE EXPRESSION PROFILING; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; HEMATOLOGIC DISEASE; IMMUNOLOGY; MACROPHAGE; PATHOLOGY;

HEMATOLOGIC NEOPLASMS; HUMANS; MACROPHAGES; TUMOR MICROENVIRONMENT;

EID: 84926421685     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12259     Document Type: Review

References (67)

1. Monis B, Weinberg T. Cytochemical study of esterase activity of human neoplasms and stromal macrophages. Cancer 1961; 14: 369-377.
2. Underwood JC, Carr I. The ultrastructure of the lymphoreticular cells in non-lymphoid human neoplasms. Virchows Arch B Cell Pathol 1972; 12: 39-50.
3. Lauder I, Aherne W, Stewart J, Sainsbury R. Macrophage infiltration of breast tumours: A prospective study. J Clin Pathol 1977; 30: 563-568.
4. Ross J, Auger M, eds. Macrophages in Tumor Biology, 2nd Ed. Oxford: Oxford Univ. Press, 2002.
5. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011; 9: 216.
6. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014; 105: 1-8.
7. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002; 196: 254-265.
8. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78.
9. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-727.
10. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008; 84: 623-630.
11. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-1073.
12. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
13. Mills CD. M1 and M2 macrophages: Oracles of health and disease. Crit Rev Immunol 2012; 32: 463-488.
14. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
15. Kaku Y, Imaoka H, Morimatsu Y etal. Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease. PLoS ONE 2014; 9: e87400.
16. Komohara Y, Hirahara J, Horikawa T etal. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006; 54: 763-771.
17. Laoui D, Movahedi K, Van Overmeire E etal. Tumor-associated macrophages in breast cancer: Distinct subsets, distinct functions. Int J Dev Biol 2011; 55: 861-867.
18. Komohara Y, Niino D, Saito Y etal. Clinical significance of CD163 tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci 2013; 104: 945-951.
19. Saito Y, Komohara Y, Niino D etal. Role of CD204-positive tumor-associated macrophages in adult T-cell leukemia/lymphoma. J Clin Exp Hematop 2014; 54: 59-65.
20. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
21. Coppleson LW, Rappaport H, Strum SB, Rose J. Analysis of the Rye classification of Hodgkin's disease. The prognostic significance of cellular composition. J Natl Cancer Inst 1973; 51: 379-390.
22. Ree HJ, Kadin ME. Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer 1985; 56: 333-338.
23. Steidl C, Lee T, Shah SP etal. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885.
24. Panico L, Ronconi F, Lepore M etal. Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma. Leuk Lymphoma 2013; 54: 2418-2425.
25. Tan KL, Scott DW, Hong F etal. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial. Blood 2012; 120: 3280-3287.
26. Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C etal. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 2012; 97: 1080-1084.
27. Yoon DH, Koh YW, Kang HJ etal. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2012; 88: 292-305.
28. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011; 52: 1913-1919.
29. Koh YW, Park C, Yoon DH, Suh C, Huh J. CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma. Am J Clin Pathol 2014; 141: 573-583.
30. Klein JL, Nguyen TT, Bien-Willner GA etal. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol 2014; 141: 381-387.
31. Barros MH, Hassan R, Niedobitek G. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: Association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res 2012; 18: 3762-3771.
32. Zaki MA, Wada N, Ikeda J etal. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011; 459: 361-366.
33. Koulis A, Trivedi P, Ibrahim H, Bower M, Naresh KN. The role of the microenvironment in human immunodeficiency virus-associated classical Hodgkin Lymphoma. Histopathology 2014; 65: 749-756.
34. Kayal S, Mathur S, Karak AK etal. CD68 tumor-associated macrophage marker is not prognostic of clinical outcome in classical Hodgkin lymphoma. Leuk Lymphoma 2014; 55: 1031-1037.
35. Casulo C, Arcila M, Bohn OL etal. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma. Leuk Res 2013; 37: 1178-1183.
36. Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012; 7: 12.
37. Azambuja D, Natkunam Y, Biasoli I etal. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012; 23: 736-742.
38. Marchesi F, Cirillo M, Bianchi A etal. High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 2014; doi: 10.1002/hon.2142.
39. Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson PO. Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 2008; 58: 529-532.
40. Yamamoto W, Nakamura N, Tomita N etal. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: Retrospective cohort study. Leuk Lymphoma 2014; 55: 2721-2727.
41. Nam SJ, Go H, Paik JH etal. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2014; 55: 2466-2476.
42. Wada N, Zaki MA, Hori Y etal. Tumour-associated macrophages in diffuse large B-cell lymphoma: A study of the Osaka Lymphoma Study Group. Histopathology 2012; 60: 313-319.
43. Farinha P, Masoudi H, Skinnider BF etal. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169-2174.
44. Kelley T, Beck R, Absi A, Jin T, Pohlman B, Hsi E. Biologic predictors in follicular lymphoma: Importance of markers of immune response. Leuk Lymphoma 2007; 48: 2403-2411.
45. Canioni D, Salles G, Mounier N etal. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440-446.
46. Byers RJ, Sakhinia E, Joseph P etal. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008; 111: 4764-4770.
47. Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 2011; 42: 552-557.
48. Andjelic B, Mihaljevic B, Todorovic M, Bila J, Jakovic L, Jovanovic MP. The number of lymphoma-associated macrophages in tumor tissue is an independent prognostic factor in patients with follicular lymphoma. Appl Immunohistochem Mol Morphol 2012; 20: 41-46.
49. Alvaro T, Lejeune M, Salvadó MT etal. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 5350-5357.
50. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppä S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13: 5784-5789.
51. de Jong D, Koster A, Hagenbeek A etal. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009; 94: 70-77.
52. Clear AJ, Lee AM, Calaminici M etal. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood 2010; 115: 5053-5056.
53. Koh YW, Shin SJ, Park C, Yoon DH, Suh C, Huh J. Absolute monocyte count predicts overall survival in mantle cell lymphomas: Correlation with tumour-associated macrophages. Hematol Oncol 2014; 32: 178-186.
54. Komohara Y, Horlad H, Ohnishi K etal. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop 2011; 51: 93-99.
55. Nie X, Clifford PM, Bhat R, Heintzelman R, Abraham M, Hou JS. Thymidine phosphorylase expression in B-cell lymphomas and its significance: A new prognostic marker? Anal Quant Cytopathol Histpathol 2013; 35: 301-305.
56. Yoshida N, Oda M, Kuroda Y etal. Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS ONE 2013; 8: e78730.
57. Chen BJ, Chapuy B, Ouyang J etal. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013; 19: 3462-3473.
58. Sakai A, Yoshida N. The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas. J Clin Exp Hematop 2014; 54: 49-57.
59. Niino D, Komohara Y, Murayama T etal. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010; 60: 278-283.
60. Sugaya M, Miyagaki T, Ohmatsu H etal. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 2012; 68: 45-51.
61. Günther C, Zimmermann N, Berndt N etal. Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma. Am J Pathol 2011; 179: 1434-1442.
62. Pedersen MB, Danielsen AV, Hamilton-Dutoit SJ etal. High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma. Histopathology 2014; 65: 490-500.
63. Suyani E, Sucak GT, Akyürek N etal. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol 2013; 92: 669-677.
64. Bai B, Horlad H, Saito Y etal. Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: The in vitro study. J Clin Exp Hematop 2013; 53: 127-133.
65. Kube D, Holtick U, Vockerodt M etal. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98: 762-770.
66. Zheng Y, Cai Z, Wang S etal. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009; 114: 3625-3628.
67. Zheng Y, Yang J, Qian J etal. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 2013; 27: 702-710.